Background: Methanol is a highly toxic, non-potable alcohol. Outbreaks of methanol toxicity occur due to its fraudulent addition to alcoholic beverages as a cheaper substitute for ethanol. Recently, alongside the coronavirus disease 2019 (COVID-19) pandemic, rumors circulated on social media that consuming alcohol can prevent or cure the virus, leading to a COVID-19 and methanol-induced optic neuropathy (MON) syndemic.

Aim: To investigate the impact of erythropoietin (EPO) on the outcomes of patients diagnosed with MON.

Methods: In this prospective study, 105 patients presenting with acute bilateral visual loss secondary to methanol intoxication were enrolled from March to May 2020 at Farabi Eye Hospital. A comprehensive ocular examination was conducted for all participants. Recombinant human EPO and methylprednisolone were administered intravenously to all patients for three consecutive days.

Results: The mean age of the participants was 39.9 years (± 12.6). Ninety-four patients were male and eleven were female. The mean pre-treatment best corrected visual acuity (BCVA) improved from 2.0 ± 0.86 to 1.39 ± 0.69 logarithm of the minimum angle of resolution post-treatment ( < 0.001), with significant improvement observed in all age categories and genders ( < 0.001). Visual acuity improvement was also significant regardless of whether the patient presented before or after 72 h ( < 0.001), and the post-treatment BCVA remained significant at all monthly follow-up visits ( < 0.001).

Conclusion: EPO and methylprednisolone therapy have been shown to be effective in improving visual outcomes in patients with MON when administrated within the first month of exposure. Public awareness efforts are necessary to prevent further outbreaks of methanol toxicity in the current COVID-19 era.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294205PMC
http://dx.doi.org/10.12998/wjcc.v11.i15.3502DOI Listing

Publication Analysis

Top Keywords

methanol-induced optic
8
optic neuropathy
8
covid-19 era
8
methylprednisolone therapy
8
outbreaks methanol
8
methanol toxicity
8
outcomes patients
8
epo methylprednisolone
8
visual acuity
8
patients
5

Similar Publications

Purpose: Despite various therapeutic attempts, an approved treatment for Methanol-induced optic neuropathy (MION), a sight-threatening disorder, is still lacking. Erythropoietin known as an erythropoietic cytokine, possesses various non-hematopoietic properties that make it a candidate for MION treatment. This systematic review aims to assess the potential therapeutic role of erythropoietin in MION.

View Article and Find Full Text PDF
Article Synopsis
  • Methanol-induced optic neuropathy (MION) is a serious health issue, especially in low-income areas with limited alcohol availability, leading to permanent vision loss due to toxic metabolites from methanol.
  • The condition causes damage to the optic nerve and retina, resulting in neurotoxicity and oxidative stress, despite improved treatments, many patients still suffer from lasting visual problems.
  • The study reviews MION's disease mechanisms, impacts on the eyes, and evaluates various treatment options while stressing the need for better awareness, diagnosis, and preventive measures to reduce its global health impact.
View Article and Find Full Text PDF

Purpose: The purpose of this study is to evaluate the visual response of methanol-induced optic neuropathy to management with erythropoietin (EPO) along with conventional therapy.

Methods: This retrospective case series examines the ophthalmological data of patients diagnosed with methanol-induced optic neuropathy between 2020 and 2021 at two centers, Riyadh, Saudi Arabia. Patients' characteristics and the results of initial and final ophthalmological examinations were documented and compared between patients who received EPO in addition to conventional management and those who received only conventional management.

View Article and Find Full Text PDF

Photobiomodulation Using Light-Emitting Diode (LED) for Treatment of Retinal Diseases.

Clin Ophthalmol

January 2024

Department of Retina, Rubens Siqueira Research Center, São José do Rio Preto, São Paulo, Brazil.

Photobiomodulation (PBM) is a type of phototherapy that employs light-emitting diodes (LEDs) or low-power lasers to selectively administer specific wavelengths of visible light, ranging from 500 to 1000 nm, including near-infrared (NIR) wavelengths. LEDs are advantageous compared to lasers due to their ability to treat large areas at a lower cost, lack of tissue damage potential in humans, and reduced risk of eye-related accidents. The ophthalmology community has recently taken interest in PBM as a promising novel approach for managing various retinal conditions such as age-related macular degeneration, retinopathy of prematurity, retinitis pigmentosa, diabetic retinopathy, Leber's hereditary optic neuropathy, amblyopia, methanol-induced retinal damage, and potentially others.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!